These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 22213014)

  • 1. Ace inhibitor therapy for heart failure in patients with impaired renal function: a review of the literature.
    Valika AA; Gheorghiade M
    Heart Fail Rev; 2013 Mar; 18(2):135-40. PubMed ID: 22213014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology.
    Mewton N; Girerd N; Boffa JJ; Courivaud C; Isnard R; Juillard L; Lamblin N; Legrand M; Logeart D; Mariat C; Meune E; Sabouret P; Sebbag L; Rossignol P
    Arch Cardiovasc Dis; 2020 Oct; 113(10):660-670. PubMed ID: 32660835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies.
    Muneer K; Nair A
    Indian Heart J; 2017; 69(3):371-374. PubMed ID: 28648436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefits and Risks of Continuing Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Antagonists, and Mineralocorticoid Receptor Antagonists during Hospitalizations for Acute Heart Failure.
    Oliveros E; Oni ET; Shahzad A; Kluger AY; Lo KB; Rangaswami J; McCullough PA
    Cardiorenal Med; 2020; 10(2):69-84. PubMed ID: 32062648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
    Sexton DJ
    Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
    [No Abstract]   [Full Text] [Related]  

  • 7. Renal functional alterations induced by angiotensin-converting enzyme inhibitors in heart failure.
    Munger MA
    Ann Pharmacother; 1993 Feb; 27(2):205-10. PubMed ID: 8439700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5).
    Leong DP; McMurray JJV; Joseph PG; Yusuf S
    J Am Coll Cardiol; 2019 Aug; 74(5):683-698. PubMed ID: 31370961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Renal Function in Type 1 Cardiorenal Syndrome.
    Ilges DT; Dermody ML; Blankenship C; Mansfield V; Van Tuyl JS
    J Cardiovasc Pharmacol Ther; 2021 Nov; 26(6):611-618. PubMed ID: 34138673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?
    Ahmed A
    J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Inhibition of renin-angiotensin-aldosterone system in heart failure, or from CONSENSUS to PARADIGM-HF].
    Vítovec J; Špinar J; Špinarová L
    Vnitr Lek; 2015 May; 61(5):470-4. PubMed ID: 26075858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the renin angiotensin system in dialysis patients.
    Cravedi P; Remuzzi G; Ruggenenti P
    Semin Dial; 2011; 24(3):290-7. PubMed ID: 21682771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advantages of renin-angiotensin system blockade in the treatment of cardiovascular diseases.
    Gerc V; Buksa M
    Med Arh; 2010; 64(5):295-9. PubMed ID: 21287956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New approaches to blockade of the renin-angiotensin-aldosterone system: evidence from randomized controlled trials (RCTs) of angiotensin-converting enzyme inhibitors and angiotensin II-receptor blockers--questions remain unsolved.
    Ueda S
    J Pharmacol Sci; 2010; 113(4):292-5. PubMed ID: 20675956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The benefits of angiotensin II receptor blockers in patients with renal insufficiency or failure.
    Venkata C; Ram S; Fierro G
    Am J Ther; 1998 Mar; 5(2):101-5. PubMed ID: 10099045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor blockers in the treatment of heart failure.
    Peterson RC; Dunlap ME
    Congest Heart Fail; 2002; 8(5):246-50; 256. PubMed ID: 12368586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of RAAS Blockers on Contrast-Induced Nephropathy in Patients With Renal Insufficiency: A Meta-Analysis.
    Huang Y; Zhang S; Liu M; Zhong X; Lin Y; Xiong Z; Fan Y; Zhou H; Sun X; Guo Y; Xu X; Li Y; Yang D; Zhuang X; Liao X
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):692-697. PubMed ID: 32889964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.